US 8119649
Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
granted A61KA61K31/506A61K31/519
Quick answer
US patent 8119649 (Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia) held by The Board of Regents of the University of Texas System expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/506, A61K31/519, A61K35/02, A61P